# Contents

1. **Mechanism of Action and Pharmacokinetics of Biologics**  
   Alan C. Moss  
   p. 1

2. **Antitumor Necrosis Factor Agents in Ulcerative Colitis**  
   Kindra Clark-Snustad, Ives Hot, and Scott Lee  
   p. 13

3. **Antitumor Necrosis Factor Agents in Crohn’s Disease**  
   Byron P. Vaughn  
   p. 33

4. **Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease**  
   David I. Fudman and Sarah N. Flier  
   p. 49

5. **Use of Biologics in the Postoperative Management of Crohn’s Disease**  
   Benjamin H. Click and Miguel Regueiro  
   p. 59

6. **Biologics in Pregnancy and Breastfeeding**  
   Jill K.J. Gaidos and Sunanda V. Kane  
   p. 81

7. **Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease**  
   Parambir S. Dulai and Corey A. Siegel  
   p. 101

8. **Therapeutic Drug Monitoring of Biologic Agents**  
   Frank I. Scott and Mark T. Osterman  
   p. 113

9. **Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks**  
   Afrin Kamal and Bret Lashner  
   p. 129

10. **Cessation of Biologics: Can It Be Done?**  
    Hang Hock Shim and Cynthia H. Seow  
    p. 141
Contents

11 Biologic Therapy in Pediatric Inflammatory Bowel Disease .......... 163
    Sonal Patel and Jennifer Strople

12 Infectious Complications of Biologics ................................. 185
    Renée M. Marchioni Beery and Joshua R. Korzenik

13 Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy .................. 213
    Julia T. Hughes and Millie D. Long

14 Noninfectious and Nonmalignant Complications of Anti-TNF Therapy ............ 231
    Uni Wong and Raymond K. Cross

15 Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, and State of
    the Finances .................. 261
    Christina Y. Ha and Asher Kornbluth

16 Anti-integrin Agents in IBD: Efficacy and Risk of Complications .................. 283
    Jimmy K. Limdi and Francis A. Farraye

17 Novel Agents in Inflammatory Bowel Disease .......................... 303
    Fernando Velayos

18 Quality, Safety, and Practical Considerations of Using Biologic Therapies ......... 315
    Leilei Zhu and Gil Y. Melmed

Index .................................................. 329
Treatment of Inflammatory Bowel Disease with Biologics
Cheifetz, A.S.; Feuerstein, J.D. (Eds.)
2018, XI, 335 p. 22 illus., 19 illus. in color., Hardcover
ISBN: 978-3-319-60275-2